<code id='C813E7612C'></code><style id='C813E7612C'></style>
    • <acronym id='C813E7612C'></acronym>
      <center id='C813E7612C'><center id='C813E7612C'><tfoot id='C813E7612C'></tfoot></center><abbr id='C813E7612C'><dir id='C813E7612C'><tfoot id='C813E7612C'></tfoot><noframes id='C813E7612C'>

    • <optgroup id='C813E7612C'><strike id='C813E7612C'><sup id='C813E7612C'></sup></strike><code id='C813E7612C'></code></optgroup>
        1. <b id='C813E7612C'><label id='C813E7612C'><select id='C813E7612C'><dt id='C813E7612C'><span id='C813E7612C'></span></dt></select></label></b><u id='C813E7612C'></u>
          <i id='C813E7612C'><strike id='C813E7612C'><tt id='C813E7612C'><pre id='C813E7612C'></pre></tt></strike></i>

          fashion

          fashion

          author:explore    Page View:882
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Readout Newsletter: Bluebird, CVS, Contineum
          Readout Newsletter: Bluebird, CVS, Contineum

          JustinSullivan/GettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetour

          read more
          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more

          Asbestos, a deadly carcinogen, banned by EPA

          EPAAdministratorMichaelReganspeaksonFeb.16,2024,inEastPalestine,Ohio.TheEPAhasannouncedacomprehensiv